Spain Pharmaceuticals & Healthcare Report Q1 2016 - New Study Released

We maintain our subdued outlook for the Spanish pharmaceutical market. Price caps on originator medicines have negatively impacted the country's generic drug sector, which lags behind other European markets. However, new measures to improve access to generic and biosimilar medicines will lead to greater opportunities for generic drugmakers operating in the country.

Headline Expenditure Projections

Pharmaceuticals: EUR24.71bn (USD33.11bn) in 2014 to EUR25.18bn (USD27.70bn) in 2015; +1.9% in local currency terms and -16.3% in US dollar terms. Forecast unchanged from last quarter.
Healthcare: EUR90.72bn (USD121.56bn) in 2014 to EUR91.69bn (USD100.86bn) in 2015; +1.1% in local currency terms and -17.0% in US dollar terms. Forecast in line with last quarter.

Full Report Details at
- http://www.fastmr.com/prod/1109847_spain_pharmaceuticals.aspx?afid=301

Risk/Reward Index

In BMI's Pharmaceutical Risk/Reward Index for Q116, Spain scored 64.4 and ranked 12th out of the 15 countries surveyed in Western Europe - just below the Netherlands (64.7). While Spain offers investors positive features, such as its large drug market, it also has problems, such as the government's focus on cost containment, low population growth, cumbersome bureaucracy and provincial differences regarding drug regulations and reimbursement.

Key Trends And Developments

The Spain Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Spain Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Spain pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Spain, to test other views - a key input for successful budgeting and strategic business planning in the Spanish pharmaceutical and healthcare market.
* Target business opportunities and risks in the Spanish pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Spain.
* Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View



About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- France Pharmaceuticals & Healthcare Report Q1 2016
- Saudi Arabia Pharmaceuticals & Healthcare Report Q1 2016
- Kenya Pharmaceuticals & Healthcare Report Q1 2016
- Ukraine Pharmaceuticals & Healthcare Report Q1 2016
- Thailand Pharmaceuticals & Healthcare Report Q1 2016